46
Participants
Start Date
July 15, 2021
Primary Completion Date
August 22, 2023
Study Completion Date
February 18, 2025
THOR-707
Solution for infusion: intravenous infusion
Cemiplimab
Solution for infusion: intravenous infusion
Investigational Site Number : 0360001, Macquarie University
Investigational Site Number : 2760004, Berlin
Investigational Site Number : 2760001, Hamburg
Investigational Site Number : 2500002, Dijon
Investigational Site Number : 2760006, Minden
Investigational Site Number : 7240002, Santander
Investigational Site Number : 2500001, Nantes
Investigational Site Number : 2500005, Lille
Investigational Site Number : 2760003, Mannheim
Investigational Site Number : 2500006, Pierre-Bénite
Investigational Site Number : 3800001, Napoli
Investigational Site Number : 2760005, München
Beverly Hills Cancer Center & Optima Diagnostic Imaging Site Number : 8400007, Beverly Hills
Investigational Site Number : 2500003, Bobigny
Investigational Site Number : 1520006, Antofagasta
Investigational Site Number : 1520003, Temuco
Investigational Site Number : 1520002, Santiago
Investigational Site Number : 1520005, Santaigo
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 1520004, Santiago
Investigational Site Number : 3800004, Perugia
Investigational Site Number : 7240001, Barcelona
Investigational Site Number : 7240004, Barcelona
Investigational Site Number : 7240003, L'Hospitalet de Llobregat
Lead Sponsor
Sanofi
INDUSTRY